BMSSC
LGND icon

B. Metzler seel. Sohn & Co’s Ligand Pharmaceuticals LGND Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Hold
6,879
– – 0.01% 474
2025
Q4 		$1.3M Buy
+6,879
New +$1.32M 0.01% 498
2021
Q1 		– Sell
-19,975
Closed -$1.28M – 691
2020
Q4 		$1.28M Buy
+19,975
New +$1.14M 0.02% 347

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

B. Metzler seel. Sohn & Co's LGND Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 6,879 shares worth $1.37M. The position accounts for 0.01% of the portfolio, ranked #474.

B. Metzler seel. Sohn & Co first reported a position in LGND in Q4 2020 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • B. Metzler seel. Sohn & Co held 6,879 shares of Ligand Pharmaceuticals worth $1.37M as of Q1 2026.
  • B. Metzler seel. Sohn & Co left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q1 2026, its #474 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Ligand Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.